Company profile
ANASTASIS BIOTEC
We are developing a novel, effective and proprietary cancer treatment
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0NDI3NTA5MmFkaXF6a2N4
Published 20 Nov 2024 12:11
AAMD | Transaction MzQzNjAxNjYxMWFkaXF6a2N4 | Paper/PDF filed
Published 19 Sep 2024 06:18
AA | Transaction MzQzNTA4MTc4OGFkaXF6a2N4
Published 10 Sep 2024 11:06
Company registered at Companies House
1 Jun 2020 to 30 Nov 2020
no public description
1 May 2019 to 31 Oct 2021
Cancer relapse and metastatic spread is a serious health problem and may be caused by the inability to destroy all residual tumour cells, particularly the residual and resistant cancer stem cell (CSC) sub-population. Killing CSC has been a major technological challenge as they share similar cell pathways and features with critical normal stem cells. NOTCH...
